By David Tuller, DrPH Ten days ago, I sent a letter to Professor Rona Moss-Morris of King’s College London, seeking information about the licensing deal involving her web-based program of cognitive behavior therapy to treat irritable bowel syndrome. Since I have not heard back, this morning I made a second attempt to reach out to …
Trial By Error: My Follow-Up Letter to Professor Rona Moss-Morris Read More »
By David Tuller, DrPH On its website, Mahana Therapeutics has listed sixteen gastroenterology and psychology advisors from prominent academic and medical institutions. Companies often add such names to their rosters as a way of signaling their significance and their access to great minds. Sometimes these people are compensated; sometimes not. In many instances, these advisors play little …
Trial By Error: My Letter to One of Mahana’s Gastroenterology Advisors Read More »
By David Tuller, DrPH Last week I wrote about the recently announced licensing deal between Mahana Therapeutics and King’s College London. The deal involves a web-based course of cognitive behavior therapy designed to treat irritable bowel syndrome. In a major study, the reported improvements in symptoms among participants in the web-based program were modest at …
Trial By Error: My Letter to Professor Moss-Morris Read More »
By David Tuller, DrPH As I wrote yesterday, Mahana Therapeutics has recently licensed from King’s College London an “innovative digital therapeutic”, a web-based program delivering a course of cognitive behavioral therapy to patients with irritable bowel syndrome. A page on the Mahana site promoting this web-delivered IBS-CBT program furthers the impression that this deal is …
Trial By Error: More on the Mahana Therapeutics Deal Read More »
By David Tuller, DrPH Yesterday I sent a freedom-of-information request to King’s College London about the recently announced licensing deal it has with Mahana Therapeutics. The deal involves a web-based CBT program for irritable bowel syndrome, which I have written about here and here. This morning I sent a note to the e-mail address for …
By David Tuller, DrPH On January 10th, the following information was announced in a press release: Mahana Therapeutics, a digital therapeutics company reimagining the treatment of chronic diseases, today announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and one of the oldest and …
Trial By Error: A Commercial Deal for King’s College London’s IBS-CBT Digital Program Read More »
